News & Events

Disc Medicine Expands Leadership Team with Industry Veterans to Advance Hepcidin Modulating Therapies Toward the Clinic

Jonathan Yu Named Senior Vice President of Corporate Strategy William Savage, MD, PhD Appointed Vice President of Clinical Development Cambridge, Mass. – August 3, 2020 – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating

More News

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from open-label BEACON trial to be presented at...

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...